CORT - Significant Move: Gary Charles Robb Invests $105K In Corcept Therapeutics Stock Options | Benzinga
In a new SEC filing on February 14, it was unveiled that Robb, Chief Business Officer at Corcept Therapeutics (NASDAQ:CORT), acquired stock options for 200,000 shares.
What Happened: Robb, Chief Business Officer at Corcept Therapeutics, acquired stock options for 200,000 shares of CORT. This information was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday. The options allow Robb to buy the company's stock at $23.01 per share.
The Wednesday morning update indicates Corcept Therapeutics shares up by 2.13%, currently priced at $23.54. At this value, Robb's 200,000 shares are worth $105,999.
About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Key Indicators: Corcept Therapeutics's Financial Health
Revenue Growth: Corcept Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 21.5%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, ...